Enhanced antibacterial activity of roxithromycin loaded pegylated poly lactide-co-glycolide nanoparticles

DARU, Journal of Pharmaceutical Sciences

Volumn 20, Issue 1, 2012, Pages

  Koopaei, Mona Noori ^a   Maghazei, Mohamad Shahab ^a   Mostafavi, Seyed Hossein ^a   Jamalifar, Hossein ^a   Samadi, Nasrin ^a   Amini, Mohsen ^a   Malek, Soheyl Jafari ^a   Darvishi, Behrad ^a   Atyabi, Fatemeh ^a   Dinarvand, Rassoul ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antibacterial; Nanoparticles; Pegylation; PLGA; Roxithromycin

Indexed keywords

NANOPARTICLE; PEGYLATED POLY LACTIDE CO GLYCOLIDE; POLYGLACTIN; ROXITHROMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; EVAPORATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; PARTICLE SIZE; PHYSICOCHEMICAL MODEL; SLOW DRUG RELEASE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; SURFACE CHARGE; SURFACE PROPERTY;

EID: 84875501994     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-20-92     Document Type: Article

References (22)

1. Changing patterns of infectious disease. Cohen ML, Nature 2000 406 762 767 10.1038/35021206 10963605
2. Antimicrobial-drug resistance. Gold HS, Moellering RC, N Engl J Med 1996 335 1445 1453 10.1056/NEJM199611073351907 8875923 (Pubitemid 26382507)
3. Molecular mechanisms that confer antibacterial drug resistance. Walsh C, Nature 2000 406 775 781 10.1038/35021219 10963607
4. Nanoantibiotics: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. Huh AJ, Kwon YJ, J Control Rel. 2011 156 2 128 145 10.1016/j.jconrel.2011.07.002
5. Development of nanoparticles for antimicrobial drug delivery. Zhang L, Pornpattananangkul D, Hu CM, Huang CM, Curr Med Chem 2010 17 585 594 10.2174/092986710790416290 20015030
6. Nanoparticles in medicine: therapeutic applications and developments. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Clin Pharmacol Ther 2008 83 5 761 769 10.1038/sj.clpt.6100400 17957183 (Pubitemid 351556021)
7. PLGA-based nanoparticles:An overview of biomedical applications. Danhier F, Ansorena E, Silva JM, Coco R, Le A, Préat V, J Control Rel. 2012 161 2 505 522 10.1016/j.jconrel.2012.01.043
8. The controlled intravenous delivery of drugs using PEG coated sterically stabilized nanospheres. Gref R, Domp A, Quellec P, Blunk T, Muller RH, Verbavatz JM, Langer R, Adv Drug Del Rev. 1995 16 215 233 10.1016/0169-409X(95)00026-4
9. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids and surfaces. Tobío M, Sánchez A, Vila A, Soriano I, Evora C, Vila-Jato J, B, Biointerfaces 2000 18 315 323 10.1016/S0927-7765(99)00157-5
10. In vitro activity of roxithromycin against Moraxella catarrhalis. Spencer RC, Wheat PF, Diagn Microbiol Infect Dis 1992 15 4 Suppl 63S 65S 1617926
11. Patil R, Thakkar S, Doke S, Boldhane S, Kakade S, Kuchekar B, Studies on Characterization, Solubility, Dissolution Rate and Antimicrobial Activity of Roxithromycin-Cyclodextrin System http://www.aapsj.org/abstracts/AM-2005/ AAPS2005-002259.pdf
12. Solid lipid nanoparticles of ciprofloxacin hydrochloride with enhanced antibacterial activity. Gandomi N, Aboutaleb E, Noori M, Atyabi F, Fazeli MR, Farbod E, J Nanosci Lett. 2012 2 21
13. Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles. Esmaeili F, Hosseini-Nasr M, Rad-Malekshahi M, Samadi N, Atyabi F, Dinarvand R, Nanomedicine: NBM. 2007 3 2 161 167 10.1016/j.nano.2007.03.003 (Pubitemid 46908907)
14. Preparation of roxithromycin-polymeric microspheres by the emulsion solvent diffusion method for taste masking. Gao Y, Cui F, Guan Y, Yang L, Wang Y, Zhang L, Int J Pharm 2006 318 1-2 62 69 16647230 (Pubitemid 43983049)
15. Docetaxel immunonanocarriers as targeted delivery systems for her2-positive tumor cells: preparation, characterization, and cytotoxicity studies. Koopaei MN, Dinarvand R, Amini M, Rabbani H, Emami S, Ostad SN, Int J 2011 6 1903 1912
16. Preparation and characterization of estradiol-loaded PLGA nanoparticles using homogenization-solvent diffusion method. Esmaeili F, Atyabi F, Dinarvand R, DARU 2008 16 196 202
17. Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines. Ebrahimnejad P, Dinarvand R, Sajadi A, Jaafari MR, Nomani AR, Azizi E, Nanomedicine: NBM. 2010 6 3 478 485 10.1016/j.nano.2009.10.003
18. Improved drug loading and antibacterial activity of minocycline-loaded PLGA nanoparticles prepared by solid/oil/water ion pairing method. Kashi TSJ, Eskandarion S, Esfandyari-Manesh M, Marashi SMA, Samadi N, Fatemi SM F, Eshraghi S, Dinarvand R, Int J Nanomed 2012 7 221 234
19. Commission CP, Pharmacopoeia of the People's Republic of China 2010 (Set of 3, English edition) 2011 23266276
20. Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles. Yadav KS, Sawant KK, AAPS PharmSciTech 2010 11 1456 465 10.1208/s12249-010-9519-4 20842542
21. Voriconazole into PLGA nanoparticles: Improving agglomeration and antifungal efficacy. Peng HS, Liu XJ, Lv GX, Sun B, Kong QF, Zhai DX, Wang Q, Zhao W, Wang GY, Wang DD, Li HL, Jin LHKN, Int J Pharm 2008 352 29 35 10.1016/j.ijpharm.2007.10.009 18053659 (Pubitemid 351273915)
22. Pharmacokinetics and distribution of a biodegradable drug-carrier. Grislain L, Couvreur P, Lenaerts V, Roland M, Deprez Decampaneere D, Speiser P, Int J Pharm 1983 15 335 345 10.1016/0378-5173(83)90166-7 (Pubitemid 13071661)